Rockwell Medical Announces Canadian Patent Issuance for Proprietary SFP-Iron Delivery

Rockwell Medical

announced today that it has received notice from the Canadian Intellectual Property Office that it has obtained patent issuance for its proprietary drug, Soluble Ferric Pyrophosphate (SFP), the Company's late-stage investigational drug that provides iron replacement to hemodialysis patients with CKD. The Canadian patent grant covers the method and pharmaceutical composition for SFP-iron delivery in hemodialysis and peritoneal dialysis patients. Mr. Robert L. Chioini, Chairman and CEO of Rockwell stated, "We are pleased to secure patent protection for SFP-iron delivery in an important market such as Canada. In conjunction with the successful completion of our SFP clinical studies, we will continue to evaluate worldwide market opportunities with an established marketing partner for the development and distribution of SFP."